No stranger to gene ther­a­py woes, Astel­las runs in­to an­oth­er safe­ty-re­lat­ed clin­i­cal hold

Astel­las Phar­ma, which has been at the fore­front of un­cov­er­ing the risks as­so­ci­at­ed with gene ther­a­pies de­liv­ered by ade­no-as­so­ci­at­ed virus­es, must take an­oth­er safe­ty alarm …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER